Investment analysts at BTIG Research assumed coverage on shares of Gain Therapeutics (NASDAQ:GANX) in a research note issued to investors on Monday, Benzinga reports. The brokerage set a “buy” rating and a $30.00 price target on the stock. BTIG Research’s price target points to a potential upside of 122.22% from the company’s previous close.
Separately, Oppenheimer began coverage on Gain Therapeutics in a research note on Monday. They set an “outperform” rating and a $30.00 price target on the stock.
NASDAQ:GANX opened at $13.50 on Monday. Gain Therapeutics has a 52-week low of $11.00 and a 52-week high of $17.93.
Gain Therapeutics, Inc, a development stage biotechnology company, develops novel therapeutics to treat rare genetic and neurological disorders caused by protein misfolding in Switzerland and Spain. The company through its in-licensed proprietary Site-Directed Enzyme Enhancement Therapy platform, discovers novel allosteric sites on misfolded proteins, identifies proprietary binding sites, and restores protein folding.
Featured Story: Why Invest in Dividend Achievers?
Receive News & Ratings for Gain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.